Clearside Biomedical (NASDAQ:CLSD – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.03, Zacks reports.
Clearside Biomedical Price Performance
Clearside Biomedical stock traded up $0.01 during midday trading on Thursday, hitting $1.03. 152,176 shares of the stock were exchanged, compared to its average volume of 356,922. Clearside Biomedical has a 1 year low of $0.77 and a 1 year high of $1.76. The firm has a market cap of $78.12 million, a P/E ratio of -2.29 and a beta of 2.10. The company has a 50 day moving average price of $0.96 and a two-hundred day moving average price of $1.05.
Analysts Set New Price Targets
CLSD has been the subject of a number of research analyst reports. StockNews.com lowered Clearside Biomedical from a “hold” rating to a “sell” rating in a research report on Tuesday, March 18th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a research report on Thursday, March 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, Clearside Biomedical currently has an average rating of “Moderate Buy” and an average target price of $5.75.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
See Also
- Five stocks we like better than Clearside Biomedical
- Do ETFs Pay Dividends? What You Need to Know
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Top 3 Beverage Stocks Pouring Out Profits
- What Investors Need to Know About Upcoming IPOs
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
